Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study
<b>Background</b>: The introduction of biological drugs into clinical practice for the treatment of children with systemic juvenile idiopathic arthritis (sJIA) allows disease control but increases the risk of infectious events. Infectious events cause immunosuppressive therapy interrupti...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/6/644 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849425777723965440 |
|---|---|
| author | Ekaterina Alexeeva Tatyana Dvoryakovskaya Dmitry Kudlay Anna Fetisova Ivan Kriulin Elizaveta Krekhova Anna Kabanova Vladimir Labinov Elizaveta Labinova Mikhail Kostik |
| author_facet | Ekaterina Alexeeva Tatyana Dvoryakovskaya Dmitry Kudlay Anna Fetisova Ivan Kriulin Elizaveta Krekhova Anna Kabanova Vladimir Labinov Elizaveta Labinova Mikhail Kostik |
| author_sort | Ekaterina Alexeeva |
| collection | DOAJ |
| description | <b>Background</b>: The introduction of biological drugs into clinical practice for the treatment of children with systemic juvenile idiopathic arthritis (sJIA) allows disease control but increases the risk of infectious events. Infectious events cause immunosuppressive therapy interruptions, leading to disease flare and life-threatening complications, namely macrophage activation syndrome. Our study aimed to evaluate the efficacy and safety of simultaneous vaccination against pneumococcal and Haemophilus influenzae type b (Hib) in children with sJIA. <b>Methods</b>: This study included 100 sJIA patients receiving immunosuppressive therapy who were simultaneously vaccinated against pneumococcal and Haemophilus influenzae type b (Hib) infections. The mean age of disease onset was 5.5 years. The median age at vaccination was 10 ± 4.5 years. Clinical and laboratory parameters of sJIA activity, immunization efficacy, and safety, including anti-SP and anti-Hib IgG antibodies, as well as all vaccination-related adverse events (AEs), were recorded in every patient before, 3 weeks after, and 6 months after vaccination. <b>Results:</b> At the time of vaccination, 29% of patients did not meet the criteria for the inactive disease stage, as defined by C. Wallace: active joints were present in 34.5% of patients, systemic manifestations (rash and/or fever) were present in 41.3%, and 24.2% of patients had solely inflammatory laboratory activity. The protective titer of anti-SP and anti-Hib IgG antibodies was detected in the majority of patients 3 weeks after vaccination (100% and 93%, respectively). The results remained unchanged (99% and 92%, respectively) for 6 months of follow-up, compared to the baseline (91% and 37%, <i>p</i> = 0.000001). Anti-SP IgG and anti-Hib titers raised from 48.3 (18.2; 76.5) and 0.64 (0.3; 3.2) U/mL at the baseline to 103.5 (47.3; 185.4) and 4 (3.5; 4.2) U/mL at D22 and 105 (48.7; 171.8) and 4 (3.8; 4) U/mL (EOS), respectively. Immunosuppressive therapy regimens (combined therapy or biological disease-modifying antirheumatic drug monotherapy) did not influence the immunogenic efficacy of vaccination. The incidence of infectious complications (<i>p</i> = 0.0000001) and antibiotic prescriptions (<i>p</i> = 0.0000001) decreased by more than two times, to 29.9 and 13.8 events per 100 patient months, respectively, within 6 months after vaccination—the average duration of acute infectious events was reduced by five times after immunization (<i>p</i> = 0.0000001). Vaccination did not lead to disease flare: the number of patients with active joints decreased by half compared to the baseline, and the number of patients with systemic manifestations decreased by six times. All vaccine-associated adverse events were considered mild and resolved within 1–2 days. <b>Conclusions</b>: Simultaneous vaccination against pneumococcal and Hib infections in sJIA children is an effective and safe tool that reduces the number and duration of infectious events and does not cause disease flare-ups. |
| format | Article |
| id | doaj-art-d90b268b1b7e402f82c344874b0dcd0c |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-d90b268b1b7e402f82c344874b0dcd0c2025-08-20T03:29:39ZengMDPI AGVaccines2076-393X2025-06-0113664410.3390/vaccines13060644Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort StudyEkaterina Alexeeva0Tatyana Dvoryakovskaya1Dmitry Kudlay2Anna Fetisova3Ivan Kriulin4Elizaveta Krekhova5Anna Kabanova6Vladimir Labinov7Elizaveta Labinova8Mikhail Kostik9Department of Pediatric Rheumatology, National Medical Research Center of Children’s Health, Moscow 119991, RussiaDepartment of Pediatric Rheumatology, National Medical Research Center of Children’s Health, Moscow 119991, RussiaDepartment of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, RussiaDepartment of Pediatric Rheumatology, National Medical Research Center of Children’s Health, Moscow 119991, RussiaDepartment of Pediatric Rheumatology, National Medical Research Center of Children’s Health, Moscow 119991, RussiaDepartment of Pediatric Rheumatology, National Medical Research Center of Children’s Health, Moscow 119991, RussiaDepartment of Pediatric Rheumatology, National Medical Research Center of Children’s Health, Moscow 119991, RussiaClinical Institute of Children’s Health Named After N.F. Filatov, Department of Pediatrics and Pediatric Rheumatology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, RussiaClinical Institute of Children’s Health Named After N.F. Filatov, Department of Pediatrics and Pediatric Rheumatology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, RussiaHospital Pediatry, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg 194100, Russia<b>Background</b>: The introduction of biological drugs into clinical practice for the treatment of children with systemic juvenile idiopathic arthritis (sJIA) allows disease control but increases the risk of infectious events. Infectious events cause immunosuppressive therapy interruptions, leading to disease flare and life-threatening complications, namely macrophage activation syndrome. Our study aimed to evaluate the efficacy and safety of simultaneous vaccination against pneumococcal and Haemophilus influenzae type b (Hib) in children with sJIA. <b>Methods</b>: This study included 100 sJIA patients receiving immunosuppressive therapy who were simultaneously vaccinated against pneumococcal and Haemophilus influenzae type b (Hib) infections. The mean age of disease onset was 5.5 years. The median age at vaccination was 10 ± 4.5 years. Clinical and laboratory parameters of sJIA activity, immunization efficacy, and safety, including anti-SP and anti-Hib IgG antibodies, as well as all vaccination-related adverse events (AEs), were recorded in every patient before, 3 weeks after, and 6 months after vaccination. <b>Results:</b> At the time of vaccination, 29% of patients did not meet the criteria for the inactive disease stage, as defined by C. Wallace: active joints were present in 34.5% of patients, systemic manifestations (rash and/or fever) were present in 41.3%, and 24.2% of patients had solely inflammatory laboratory activity. The protective titer of anti-SP and anti-Hib IgG antibodies was detected in the majority of patients 3 weeks after vaccination (100% and 93%, respectively). The results remained unchanged (99% and 92%, respectively) for 6 months of follow-up, compared to the baseline (91% and 37%, <i>p</i> = 0.000001). Anti-SP IgG and anti-Hib titers raised from 48.3 (18.2; 76.5) and 0.64 (0.3; 3.2) U/mL at the baseline to 103.5 (47.3; 185.4) and 4 (3.5; 4.2) U/mL at D22 and 105 (48.7; 171.8) and 4 (3.8; 4) U/mL (EOS), respectively. Immunosuppressive therapy regimens (combined therapy or biological disease-modifying antirheumatic drug monotherapy) did not influence the immunogenic efficacy of vaccination. The incidence of infectious complications (<i>p</i> = 0.0000001) and antibiotic prescriptions (<i>p</i> = 0.0000001) decreased by more than two times, to 29.9 and 13.8 events per 100 patient months, respectively, within 6 months after vaccination—the average duration of acute infectious events was reduced by five times after immunization (<i>p</i> = 0.0000001). Vaccination did not lead to disease flare: the number of patients with active joints decreased by half compared to the baseline, and the number of patients with systemic manifestations decreased by six times. All vaccine-associated adverse events were considered mild and resolved within 1–2 days. <b>Conclusions</b>: Simultaneous vaccination against pneumococcal and Hib infections in sJIA children is an effective and safe tool that reduces the number and duration of infectious events and does not cause disease flare-ups.https://www.mdpi.com/2076-393X/13/6/644systemic juvenile idiopathic arthritissJIAvaccinespneumococcal vaccineHaemophilus influenzae type b vaccineHib vaccine |
| spellingShingle | Ekaterina Alexeeva Tatyana Dvoryakovskaya Dmitry Kudlay Anna Fetisova Ivan Kriulin Elizaveta Krekhova Anna Kabanova Vladimir Labinov Elizaveta Labinova Mikhail Kostik Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study Vaccines systemic juvenile idiopathic arthritis sJIA vaccines pneumococcal vaccine Haemophilus influenzae type b vaccine Hib vaccine |
| title | Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study |
| title_full | Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study |
| title_fullStr | Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study |
| title_full_unstemmed | Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study |
| title_short | Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study |
| title_sort | safety and efficacy of simultaneous vaccination with polysaccharide conjugate vaccines against pneumococcal 13 valent vaccine and haemophilus type b infections in children with systemic juvenile idiopathic arthritis prospective cohort study |
| topic | systemic juvenile idiopathic arthritis sJIA vaccines pneumococcal vaccine Haemophilus influenzae type b vaccine Hib vaccine |
| url | https://www.mdpi.com/2076-393X/13/6/644 |
| work_keys_str_mv | AT ekaterinaalexeeva safetyandefficacyofsimultaneousvaccinationwithpolysaccharideconjugatevaccinesagainstpneumococcal13valentvaccineandhaemophilustypebinfectionsinchildrenwithsystemicjuvenileidiopathicarthritisprospectivecohortstudy AT tatyanadvoryakovskaya safetyandefficacyofsimultaneousvaccinationwithpolysaccharideconjugatevaccinesagainstpneumococcal13valentvaccineandhaemophilustypebinfectionsinchildrenwithsystemicjuvenileidiopathicarthritisprospectivecohortstudy AT dmitrykudlay safetyandefficacyofsimultaneousvaccinationwithpolysaccharideconjugatevaccinesagainstpneumococcal13valentvaccineandhaemophilustypebinfectionsinchildrenwithsystemicjuvenileidiopathicarthritisprospectivecohortstudy AT annafetisova safetyandefficacyofsimultaneousvaccinationwithpolysaccharideconjugatevaccinesagainstpneumococcal13valentvaccineandhaemophilustypebinfectionsinchildrenwithsystemicjuvenileidiopathicarthritisprospectivecohortstudy AT ivankriulin safetyandefficacyofsimultaneousvaccinationwithpolysaccharideconjugatevaccinesagainstpneumococcal13valentvaccineandhaemophilustypebinfectionsinchildrenwithsystemicjuvenileidiopathicarthritisprospectivecohortstudy AT elizavetakrekhova safetyandefficacyofsimultaneousvaccinationwithpolysaccharideconjugatevaccinesagainstpneumococcal13valentvaccineandhaemophilustypebinfectionsinchildrenwithsystemicjuvenileidiopathicarthritisprospectivecohortstudy AT annakabanova safetyandefficacyofsimultaneousvaccinationwithpolysaccharideconjugatevaccinesagainstpneumococcal13valentvaccineandhaemophilustypebinfectionsinchildrenwithsystemicjuvenileidiopathicarthritisprospectivecohortstudy AT vladimirlabinov safetyandefficacyofsimultaneousvaccinationwithpolysaccharideconjugatevaccinesagainstpneumococcal13valentvaccineandhaemophilustypebinfectionsinchildrenwithsystemicjuvenileidiopathicarthritisprospectivecohortstudy AT elizavetalabinova safetyandefficacyofsimultaneousvaccinationwithpolysaccharideconjugatevaccinesagainstpneumococcal13valentvaccineandhaemophilustypebinfectionsinchildrenwithsystemicjuvenileidiopathicarthritisprospectivecohortstudy AT mikhailkostik safetyandefficacyofsimultaneousvaccinationwithpolysaccharideconjugatevaccinesagainstpneumococcal13valentvaccineandhaemophilustypebinfectionsinchildrenwithsystemicjuvenileidiopathicarthritisprospectivecohortstudy |